ARDIA PRECISION HEALTHGoverned AI for healthcare revenue & precision care
Back to Home
🏗️ WHAT WE'RE BUILDING — ARDIA PRECISION HEALTH

AI-Native Revenue Recovery
for Healthcare Labs & Clinics

Ardia is building an AI-native platform that reasons about clinical documentation, argues denied claims, and generates evidence-backed recovery narratives that a licensed reviewer approves before submission — with a target turnaround under 90 seconds.

✅ Phase 1 — Active Development ⚡ Pre-Revenue · Seed Stage 📍 DFW Pilot Target: Q4 2026 🗓️ Founded December 2025 · Delaware C-Corporation ☁️ Building on Google Cloud (Vertex AI) · planned under BAA
⚡ Watch Models 🧪 Try 90-Second Free Trial

What Ardia Is Building

A multi-module AI revenue intelligence platform purpose-built for independent labs, specialty practices, and value-based care organizations across the United States.

🧠
TARA Engine
A three-layer architecture combining neural networks (LLMs), symbolic rule engines (LCD/NCD logic), and clinical knowledge graphs. Produces explainable, citation-backed appeal narratives — designed to minimise hallucinations through symbolic validation and citation grounding.
⚖️
Payer-Side Insider Intelligence
Our co-founder spent 12+ years inside Cigna, UnitedHealth, Optum, and Teladoc building the denial logic Ardia defeats. A rare payer-side perspective few RCM vendors have.
💰
Zero-Risk Contingency Model
The model is designed so labs pay 15% of recovered revenue only when they win — no upfront cost, no implementation fees. Recovered revenue, not fees, is meant to fund the platform. We win when you win.
Transparency Note: Ardia Precision Health, Inc. was founded in December 2025. We are pre-revenue and in active Phase 1 development. The platform shown below is a functional prototype demonstrating our AI denial intelligence architecture. ToxIQ™ and MolecuIQ™ are targeting Q4 2026 for our first DFW pilot launch. PulmoIQ™ (pulmonary RCM) and Meridian™ (our deterministic PAMA rate-cliff model) are on our 2027 roadmap. We are raising a seed round to accelerate development and pilot deployment.

Where We Are Right Now

Four product modules across a phased rollout — from active Phase 1 development through our 2027–2028 expansion roadmap.

Phase 1 · Q4 2026
ToxIQ™
Toxicology Revenue Intelligence
AI-driven denial prevention and appeal automation for urine drug screening (G0480–G0483) and definitive drug testing (80300–80377 CPT codes). Highest-volume denial segment for independent labs.
  • ✓ Medical necessity validation per payer LCD
  • ✓ Quantity limits & frequency checking
  • ✓ Presumptive-to-definitive bundling compliance
  • ✓ Automated appeal brief generation
Architecture complete · DFW pilot outreach active
Phase 1 · Primary
MolecuIQ™
Precision Medicine — Molecular & Genomic RCM
Precision-medicine RCM for genomics and pharmacogenomics: MolDX/DEX Z-code automation, NGS panels (81445/81455), and PGx testing (CYP2C19/2D6), with claims matched to NCCN and CPIC guidelines. The most complex, highest-value billing module in lab medicine.
  • ✓ MolDX DEX Z-code assignment automation
  • ✓ PGx (CYP2C19/2D6) CPIC-matched prior auth
  • ✓ NGS (81445/81455) NCCN guideline alignment
  • ✓ AI appeal with clinical evidence citations
Architecture complete · DFW molecular labs targeted Q4 2026
Phase 2 · 2027
Meridian™
Deterministic PAMA Rate-Cliff Model
A deterministic engine that models the 2027 PAMA Clinical Laboratory Fee Schedule rate cuts test-by-test, quantifying each lab's exposure to the reimbursement cliff so pricing and volume decisions can be made before the cuts land. Modelled projections only — not financial advice.
  • ◦ Test-by-test PAMA CLFS rate-cut modelling
  • ◦ Per-lab reimbursement exposure estimates
  • ◦ Deterministic — same inputs, same auditable output
Design phase · Phase 2 roadmap 2027
Phase 3 · 2027–28
PulmoIQ™
Pulmonary & Respiratory Revenue Intelligence
Denial prevention and appeal automation for pulmonary and respiratory care — pulmonary function testing, sleep studies, and respiratory pathogen panels — extending Ardia's RCM engine into a new clinical specialty. Modelled targets only.
  • ◦ PFT & spirometry medical-necessity validation
  • ◦ Sleep study (polysomnography) prior auth
  • ◦ Respiratory panel bundling & frequency checks
Roadmap phase · Phase 3 target 2027–2028

See the Prototype in Action

Two interactive prototype environments running on synthetic data. Click through the model demos and the 90-second trial — both built and interactive.

ardiahealthlabs.com/studio
● DEMO
Watch Models
Interactive model demos on synthetic data — watch each model reason through a denial queue, recovery trend, and AI activity feed.
Watch Models →
🧪
90-Second Free Trial
Paste any denied claim. Watch the TARA generate a payer-formatted appeal brief with clinical citations, LCD references, and recovery arguments — in under 90 seconds. No signup required.
Try It Free — No Signup →

What the Platform Looks Like

Screenshots from the working prototype. The reasoning engine runs on Anthropic Claude today; GCP Vertex AI, Cloud Healthcare API and FHIR R4 pipelines are planned under BAA.

ardiahealthlabs.com/studio
Ardia Model Demos — Revenue Recovery Intelligence

Ardia Model Demos — denial queue, recovery trend chart, denial code breakdown, and AI activity feed. Interactive prototype on synthetic data — recovery workflow benchmarked against a $118 avg manual appeal (Change Healthcare 2023).

ardiahealthlabs.com/plg-sandbox.html
Ardia 90-Second AI Trial — Appeal Brief Generator

Ardia 90-Second AI Trial — Paste a denied claim, watch the TARA engine reason through it, and get a full payer-formatted appeal brief with clinical citations.

How It's Built

Ardia's Triadic Adjudicative Reasoning Architecture (TARA) combines three AI layers to produce explainable, citation-backed clinical appeal narratives at scale.

🧠
Layer 1 — Neural (LLM)
Anthropic Claude as the clinical reasoning engine. Reads EHR notes, lab results, and genomic reports. Generates human-quality narrative arguments with medical citations.
Claude AIVertex AINLP
⚙️
Layer 2 — Symbolic (Rules Engine)
Targeting 400+ payer-specific LCD/NCD policies, with planned scheduled CMS policy ingestion. Validates every claim against the exact rules payers use to deny it — so our AI argues the right fight.
LCD/NCD Rules400+ Payer PoliciesCMS Sync
🔗
Layer 3 — Knowledge Graph
Clinical knowledge graph linking CPT codes, ICD-10 diagnoses, NCCN guidelines, PLA codes, and Z-codes. Provides evidence-based clinical context for every denial argument.
NCCNFHIR R4PLA CodesZ-codes
☁️
Google Cloud Platform
Planned under BAA: GCP Vertex AI, Cloud Healthcare API for FHIR R4 pipelines, and BigQuery for denial analytics. The current prototype runs on Vercel + Anthropic Claude.
GCP · plannedVertex AI · plannedBigQuery · plannedHIPAA
📡
Integration Layer
EDI 835/837 clearinghouse integration. Planned direct API connections to major lab billing systems. HL7/FHIR R4 interoperability. Designed to scale to high claim volumes with no EHR integration required for Phase 1.
EDI 835/837HL7API-first
🔒
Compliance by Design
Designed to comply with TX SB 1188. TRAIGA AI transparency standards. HIPAA BAA-ready. FCA safe harbor architecture. Every AI output requires licensed professional review before submission per SB 1188.
SB 1188TRAIGAHIPAAFCA

Where We're Headed

A six-phase roadmap from DFW pilot to national and global expansion — targeting the $70B+ AI-in-RCM market (Grand View Research 2024).

Dec 2025
Company Founded ✅
Ardia Precision Health, Inc. incorporated in Delaware. Platform architecture designed. Core AI engine built. ToxIQ™ and MolecuIQ™ development active.
CompletedDelaware C-CorporationDallas–Fort Worth, TX
Q4 2026
Phase 1 — DFW Pilot Launch 🎯
First 3–5 independent lab pilots in Dallas-Fort Worth. ToxIQ™ and MolecuIQ™ live with real denial data. Target: first paid DFW pilots (ToxIQ™ + MolecuIQ™) and measurable ROI data for Series A.
ToxIQ™MolecuIQ™Pilot Outreach Active
Q3–Q4 2026
Phase 1 Expansion — Texas Scale
Expand to 25–50 Texas labs. Salesforce CRM for distribution. PAMA 2027 rate cliff positioning as key sales driver. Seed round deployment.
Seed RaiseCRM DistributionTexas Scale
2027
Phase 2 — Meridian™ + National Labs
Meridian™, our deterministic PAMA rate-cliff model, launches as the 2027 PAMA CLFS cuts take effect — quantifying each lab's exposure and turning the rate cliff into a positioning advantage. Expand across national independent labs. Series A fundraise.
Meridian™Series APAMA 2027
2027–28
Phase 3 — PulmoIQ™ + Hospital Systems
PulmoIQ™ extends the RCM engine into pulmonary and respiratory care. Expand to hospital outreach labs and specialty practices. Modelled targets only — no revenue or client results claimed pre-launch.
PulmoIQ™Hospital LabsModelled Target
2029+
Phase 4–6 — Global & Payer Markets
International expansion (UK NHS, EU healthcare). Payer-side licensing. Genomics market entry. AI-native claims clearinghouse. Target: national expansion across the independent-lab RCM market.
GlobalPayer-Side$70B+ AI-RCM

Ready to See It in Action?

Try the 90-second free trial, watch the model demos, or book a demo with our team directly.

🧪 Try Free — No Signup ⚡ Watch Models 📅 Book a Demo
45%
Manual Appeal Success · HFMA 2024
15%
Contingency · on recovery
<90s
Target · Full Appeal Draft
30 days
Target · Time to First ROI